Author/Authors :
Ashraf Ahmed, Ossama Internal Medicine Department - Gastroenterology and Hepatology Unit - Ain Shams University - Cairo, Egypt , Safwat, Eslam Internal Medicine Department - Gastroenterology and Hepatology Unit - Ain Shams University - Cairo, Egypt , Khalifa, Mohamed Omar Tropical Medicine Department - Ain Shams University - Cairo, Egypt , Elshafie, Ahmed I. Internal Medicine Department - Gastroenterology and Hepatology Unit - Ain Shams University - Cairo, Egypt , Ahmed Fouad, Mohamed Hassan Internal Medicine Department - Gastroenterology and Hepatology Unit - Ain Shams University - Cairo, Egypt , Magdy Salama, Mohamed Internal Medicine Department - Gastroenterology and Hepatology Unit - Ain Shams University - Cairo, Egypt , Gamal Naguib, Gina Internal Medicine Department - Gastroenterology and Hepatology Unit - Ain Shams University - Cairo, Egypt , Eltabbakh, Mohamed Mahmoud Tropical Medicine Department - Ain Shams University - Cairo, Egypt , Fouad Sherief, Ahmed Tropical Medicine Department - Ain Shams University - Cairo, Egypt , Abd-Elsalam, Sherief Tropical Medicine & Infectious Diseases Department - Tanta University - Tanta, Egypt
Abstract :
Background and Aims. As indicated by the World Health Organization (WHO), Egypt is positioned as the country with the world’s
highest prevalence of Hepatitis C virus (HCV). HCV is transmitted through unexamined blood transfusions, diferent employments
of syringes, and poor cleansing, as per the WHO. Our study aimed at screening and management of chronic hepatitis C genotype 4
infected patients in Bardeen village, Sharkeya Governorate, Egypt, with Sofosbuvir plus Daclatasvir, as well as estimating the safety
and efcacy of that regimen. Methods. Screening of adult patients in Bardeen village was done from March 2016 till November 2016
using hepatitis C virus antibodies by third-generation ELISA testing. Positive results were confrmed by PCR. Patients eligible for
treatment received Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and were assessed for sustained virologic response
at 12 weeks following the end of treatment (SVR 12). Results. Out of 2047 subjects screened for hepatitis C virus, 249 (12.2%) showed
positive results. 221 out of those 249 subjects (88.7%) had detectable RNA by PCR. Treatment of eligible patients (183 patients) with
Sofosbuvir plus Daclatasvir for 12 weeks resulted in 96% achievement of sustained virologic response at week 12. Adverse events
were tolerable. Conclusion. Sofosbuvir plus Daclatasvir regimen is safe and efective for treatment of chronic hepatitis C Genotype 4
infected patients with minimal adverse events. HCV eradication program implemented in Egypt can be a model for other countries with HCV and limited resources. The availability of generic drugs in Egypt will help much in eradication of the virus.
Keywords :
Hepatitis C virus , HCV , Sofosbuvir Plus Daclatasvir , Chronic Hepatitis C , Genotype 4 Infection , Cohort , Egyptian Patients , Egyptian Village
